Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2024-07-03 Legal Proceedings Report
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Updates
Legal Proceedings Report Classification · 95% confidence The document is a disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about a legal order received from the Income-tax Appellate Tribunal (ITAT) related to a tax dispute for the assessment year 2016-17. It includes details of the dispute, the tribunal involved, and the potential financial impact. The document is addressed to stock exchanges and is a regulatory announcement about a legal proceeding rather than a full legal proceedings report or financial report. It does not contain detailed financial statements or management discussion but is a compliance disclosure about a legal matter. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is 3688 characters, which is relatively short but contains substantive information about the legal matter, not just a brief announcement or certification. Hence, it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2024-07-03 English
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that our current Site Lead India Operations - Ms. Mina Patel is completing her international assignment ....
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding a change in senior management personnel, specifically the appointment of a new Site Lead for India Operations. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes details about the appointment and profile of the new appointee. There are no financial statements, earnings data, or report attachments. The content clearly fits the category of announcements about changes in the company's board or senior management.
2024-07-03 English
Updates
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) disclosing a change in senior management personnel, specifically the appointment of Mr. Srikanth B.S. as Site Lead, India Operations effective August 1, 2024. It references compliance with SEBI regulations regarding disclosure of such changes. The content focuses on management role changes and includes details about the new appointee's profile. There is no financial data, earnings information, or report publication mentioned. The document fits the category of announcements related to changes in the company's board or senior management.
2024-07-03 English
Please find the enclosed document of the Company as per the captioned subject for your reference.
Regulatory Filings
2024-07-01 English
Shareholders meeting
Regulatory Filings
2024-07-01 English
Pursuant to Regulation 39(3) and other applicable of SEBI (LODR) Regulations, 2015, we would like to inform you that the RTA of the Company have informed the Company on the enclosed request ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) regarding the loss of a share certificate by a shareholder. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 39(3), which pertains to share certificate loss and related procedures. The content is an announcement of an event (loss of share certificate) and the company's intention to issue a Letter of Confirmation after formalities are completed. There is no financial data, no report attached or referenced as being published, no management discussion, no voting results, no capital changes, or other report types. This fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2024-06-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.